AbbVie (ABBV), 88% efficacy over 5 years and safety verified for up to 6 years... Highlighting the "long-term competitiveness" in dermatology.

AbbVie (ABBV) has once again highlighted its competitive strength in global markets for “sustainability” and “safety” by extensively disclosing long-term clinical data and real-world evidence in the field of dermatology and disease treatment. In particular, as synchronized confirmations have been obtained regarding the long-term efficacy of its key therapeutic drugs and the improvements in quality of life, the assessment believes that the credibility of its entire immunology disease product portfolio has been further strengthened.

AbbVie announced that it will present a total of 24 research abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held from the 27th to the 31st (local time). The data to be released covers clinical and real-world treatment data across major dermatology areas such as psoriasis, atopic dermatitis, vitiligo, and alopecia areata.

The most closely watched results are the long-term efficacy of the psoriasis treatment drug risankizumab (RZQ). According to the company, the data show that the proportion of patients without imaging disease progression within 5 years reaches 88%. This is a case of effectively suppressing disease worsening—an indicator of particular importance within a long-term treatment strategy.

Another core drug, upadacitinib, based on data from more than 9,000 patient-years, has had its safety confirmed for as long as 6 years. The analysis suggests that because consistent results were obtained across different age groups, the drug is also expected to become a stable choice in real-world prescribing settings.

The quality-of-life improvement effects have also been confirmed by the data. The highest achievement rate for the dermatology patients’ quality-of-life measure DLQI 0/1 reaches up to 88.9%, emphasizing that clinical improvements bring tangible changes to patients’ day-to-day lives. Industry evaluations say that this “confirms that it has moved beyond simply alleviating symptoms, evolving into ‘patient-centered treatment.’”

At the same time, results were also released for vitiligo and alopecia areata treatments that are in Phase 3 clinical trials. In particular, the latest upadacitinib research on vitiligo will be included in a “delayed release” format, which is expected to attract attention at the conference on-site.

On the regulatory front, positive developments have also come one after another. The FDA supplemental approval label update for risankizumab regarding expanding indications for genital and scalp psoriasis treatment has been updated. This move is expected to broaden the scope of treatment while enhancing its market competitiveness.

Wall Street assessments believe that through this release, AbbVie’s “differentiation strategy,” built on long-term data accumulation, has become clear. A biotech investment expert said, “Compared with short-term effects, proving long-term safety and sustained efficacy has become the core of competition among recently developed treatment drugs,” and “AbbVie is one of the companies with the most cutting-edge data in this field.”

Commentary: This release is not only interpreted as a straightforward announcement of research results, but also as a signal that AbbVie is strengthening its long-term leading position in the immunology disease and dermatology treatment markets.